Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

57.1%

4 terminated/withdrawn out of 7 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1

5(83.3%)

Phase 3

1(16.7%)

6Total

Phase 1(5)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05826535Phase 1Recruiting

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

Role: lead

NCT07188558Phase 3Recruiting

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

Role: lead

NCT05319314Phase 1Recruiting

GCC19CART for Patients With Metastatic Colorectal Cancer

Role: lead

NCT05891197Terminated

A Biomarker Screening Protocol for Participants With Solid Tumors

Role: lead

NCT05274451Phase 1Terminated

A Study to Investigate LYL797 in Adults With Solid Tumors

Role: lead

NCT05573035Phase 1Terminated

A Study to Investigate LYL845 in Adults With Solid Tumors

Role: lead

NCT06153095Phase 1Withdrawn

A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Role: lead

All 7 trials loaded